Tau: From research to clinical development

David M. Holtzman; Maria C. Carrillo; James A. Hendrix; Lisa J. Bain; Ana M. Catafau; Laura M. Gault; Michel Goedert; Eckhard Mandelkow; Eva Maria Mandelkow; David S. Miller; Susanne Ostrowitzki; Manuela Polydoro; Sean Smith; Marion Wittmann; Michael Hutton

doi:10.1016/j.jalz.2016.03.018

Tau: From research to clinical development

David M. Holtzman, Maria C. Carrillo, James A. Hendrix, Lisa J. Bain, Ana M. Catafau, Laura M. Gault, Michel Goedert, Eckhard Mandelkow, Eva Maria Mandelkow, David S. Miller, Susanne Ostrowitzki, Manuela Polydoro, Sean Smith, Marion Wittmann, Michael Hutton

Research output: Contribution to journal › Review article › peer-review

108 Scopus citations

Abstract

Alzheimer's Association Research Roundtable Fall 2015—Tau: From research to clinical development. Tau pathology is recognized as the key driver of disease progression in Alzheimer's and other neurodegenerative diseases. Although this makes tau an attractive target for the development of novel diagnostic and therapeutic strategies, the mechanisms underlying the onset and progression of tau-related neurotoxicity remain elusive. Recent strides in the development of sophisticated preclinical models and the emergence of tau PET imaging and fluid biomarkers provide new opportunities to increase our understanding of tau biology, overcome translational challenges, and accelerate the advancement of tau therapeutics from bench to bedside. With this in mind, the Alzheimer's Association convened a Research Roundtable in October 2015, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of tau pathogenic pathways and review the evolution of tau therapeutics and biomarkers currently in development. The meeting provided a forum to share experience and expertise with the common goal of advancing the discovery and development of new treatment strategies and expediting the design and implementation of efficient clinical trials.

Original language	English
Pages (from-to)	1033-1039
Number of pages	7
Journal	Alzheimer's and Dementia
Volume	12
Issue number	10
DOIs	https://doi.org/10.1016/j.jalz.2016.03.018
State	Published - Oct 1 2016

Keywords

Alzheimer's disease
Biomarkers
Neurofibrillary tangles
Tau
Tauopathies

Access to Document

10.1016/j.jalz.2016.03.018

Cite this

@article{db69038e33f54c3d841c4867e57dc96b,

title = "Tau: From research to clinical development",

abstract = "Alzheimer's Association Research Roundtable Fall 2015—Tau: From research to clinical development. Tau pathology is recognized as the key driver of disease progression in Alzheimer's and other neurodegenerative diseases. Although this makes tau an attractive target for the development of novel diagnostic and therapeutic strategies, the mechanisms underlying the onset and progression of tau-related neurotoxicity remain elusive. Recent strides in the development of sophisticated preclinical models and the emergence of tau PET imaging and fluid biomarkers provide new opportunities to increase our understanding of tau biology, overcome translational challenges, and accelerate the advancement of tau therapeutics from bench to bedside. With this in mind, the Alzheimer's Association convened a Research Roundtable in October 2015, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of tau pathogenic pathways and review the evolution of tau therapeutics and biomarkers currently in development. The meeting provided a forum to share experience and expertise with the common goal of advancing the discovery and development of new treatment strategies and expediting the design and implementation of efficient clinical trials.",

keywords = "Alzheimer's disease, Biomarkers, Neurofibrillary tangles, Tau, Tauopathies",

author = "Holtzman, {David M.} and Carrillo, {Maria C.} and Hendrix, {James A.} and Bain, {Lisa J.} and Catafau, {Ana M.} and Gault, {Laura M.} and Michel Goedert and Eckhard Mandelkow and Mandelkow, {Eva Maria} and Miller, {David S.} and Susanne Ostrowitzki and Manuela Polydoro and Sean Smith and Marion Wittmann and Michael Hutton",

note = "Funding Information: Funding: DMH: Tau Consortium , The JPB Foundation , NIH grants NS090934 , AG04867801 . Publisher Copyright: {\textcopyright} 2016 The Alzheimer's Association",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.jalz.2016.03.018",

language = "English",

volume = "12",

pages = "1033--1039",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

number = "10",

}

TY - JOUR

T1 - Tau

T2 - From research to clinical development

AU - Holtzman, David M.

AU - Carrillo, Maria C.

AU - Hendrix, James A.

AU - Bain, Lisa J.

AU - Catafau, Ana M.

AU - Gault, Laura M.

AU - Goedert, Michel

AU - Mandelkow, Eckhard

AU - Mandelkow, Eva Maria

AU - Miller, David S.

AU - Ostrowitzki, Susanne

AU - Polydoro, Manuela

AU - Smith, Sean

AU - Wittmann, Marion

AU - Hutton, Michael

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Alzheimer's Association Research Roundtable Fall 2015—Tau: From research to clinical development. Tau pathology is recognized as the key driver of disease progression in Alzheimer's and other neurodegenerative diseases. Although this makes tau an attractive target for the development of novel diagnostic and therapeutic strategies, the mechanisms underlying the onset and progression of tau-related neurotoxicity remain elusive. Recent strides in the development of sophisticated preclinical models and the emergence of tau PET imaging and fluid biomarkers provide new opportunities to increase our understanding of tau biology, overcome translational challenges, and accelerate the advancement of tau therapeutics from bench to bedside. With this in mind, the Alzheimer's Association convened a Research Roundtable in October 2015, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of tau pathogenic pathways and review the evolution of tau therapeutics and biomarkers currently in development. The meeting provided a forum to share experience and expertise with the common goal of advancing the discovery and development of new treatment strategies and expediting the design and implementation of efficient clinical trials.

AB - Alzheimer's Association Research Roundtable Fall 2015—Tau: From research to clinical development. Tau pathology is recognized as the key driver of disease progression in Alzheimer's and other neurodegenerative diseases. Although this makes tau an attractive target for the development of novel diagnostic and therapeutic strategies, the mechanisms underlying the onset and progression of tau-related neurotoxicity remain elusive. Recent strides in the development of sophisticated preclinical models and the emergence of tau PET imaging and fluid biomarkers provide new opportunities to increase our understanding of tau biology, overcome translational challenges, and accelerate the advancement of tau therapeutics from bench to bedside. With this in mind, the Alzheimer's Association convened a Research Roundtable in October 2015, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of tau pathogenic pathways and review the evolution of tau therapeutics and biomarkers currently in development. The meeting provided a forum to share experience and expertise with the common goal of advancing the discovery and development of new treatment strategies and expediting the design and implementation of efficient clinical trials.

KW - Alzheimer's disease

KW - Biomarkers

KW - Neurofibrillary tangles

KW - Tau

KW - Tauopathies

UR - http://www.scopus.com/inward/record.url?scp=84970005269&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.03.018

DO - 10.1016/j.jalz.2016.03.018

M3 - Review article

C2 - 27154059

AN - SCOPUS:84970005269

SN - 1552-5260

VL - 12

SP - 1033

EP - 1039

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 10

ER -

Tau: From research to clinical development

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this